紅星美凱龍(01528.HK):至去年底監事會主席等累計增持資金已超增持計劃50%
紅星美凱龍(01528.HK)公布,截至2019年12月31日,公司部份董事、高級管理人員及監事會主席已於近期通過上海證券交易所合計增持364.67萬股股份,佔公司總股本的0.1027%。增持後,該等人員合計持有公司438.7萬股股份,佔公司總股本的0.1236%。
截至2019年12月31日,該等人員已合計累計耗資4,172.89萬元人民幣自願增持公司股份374.67萬股股份,合計累計增持資金已超過此次增持計劃的50%。此次增持計劃可能存在因資本市場情況發生變化等因素,導致增持計劃無法實施完畢的風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.